Epassi Group Expands into Southern Europe with the Acquisition of VIP District
Epassi Group’s acquisition of VIP District (www.vipdistrict.com) marks a major milestone in Epassi’s pan-European growth strategy and follows Epassi’s recent acquisition of Zest in the UK, which expanded the Group’s UK footprint and enhanced its overall employee benefits software offering. With VIP District now part of the Epassi family, the Group significantly expands its footprint into Spain and Portugal, while strengthening its existing presence in Italy, Germany, and the Netherlands.
Founded in 2010, VIP District supports over 3,000 companies with its digital platform, offering exclusive employee rewards and incentives, recognition tools, and engagement solutions. The company has become a leader in Southern Europe, helping employers boost retention, satisfaction, and wellbeing.
“This partnership accelerates our ambition to build the leading European tech platform for employee benefits and wellbeing,” said Pekka Rantala, CEO of Epassi Group. “VIP District brings a strong market position, an excellent team, and a shared passion for innovation and employee experience. Together, we are strengthening our reward services proposition across Europe, delivering even more value to our clients and their employees.”
The combination unites two highly complementary platforms – Epassi’s multi-benefit platform and VIP District’s engagement and reward services – creating a unique, scalable offering that enables employers to engage, recognize, and reward their employees with greater impact and flexibility.
“VIP District has always focused on innovation and strategic, sustainable growth,” said Jesús Alonso, CEO of VIP District. “Today’s partnership with Epassi is the latest step in our mission to become the preferred all in one employee engagement platform with benefits, employee discounts, internal communication, recognition and rewards across Europe. By combining forces, we can deliver even more value to our customers—helping them attract, motivate, and retain talent in a dynamic market.”
This acquisition further solidifies Epassi’s position as a European leader in the employee benefits ecosystem, now serving over 45,000 employers and more than 29 million users across the Nordics, UK, Ireland, Germany, the Netherlands, Italy, Spain, Portugal, and France.
About Epassi
Founded in 2007, Epassi is a leading provider of employee benefits technology operating across Finland, Sweden, Germany, the Netherlands, Italy, the UK and Ireland. Epassi’s innovative, mobile and digital first platform serves around 46,000 employers and their more than 29 million employees, partnering with over 97,000 service providers across its benefits ecosystem.
Epassi has been recognized by the Financial Times as one of the fastest growing companies in Europe in 2022, 2023, 2024, and 2025. Epassi was ranked 32nd on “Europe’s Long-term Growth Champions 2025” list.
Epassi – Boosting everyday well-being.
About VIP District
Founded in 2010, VIP District provides digital engagement solutions that help companies enhance employee experience through rewards, recognition, internal communication and exclusive discounts. Headquartered in Madrid and offices in 8 locations, the company serves over 3,000 employers and 7 million users across Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616658244/en/
Contacts
Press Contacts
Seven Consultancy: epassi@seven-consultancy.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing17.6.2025 14:00:00 EEST | Press release
In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617098086/en/ Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano） Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen’s proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. 120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights The RenNano® platform employs a large-fragment knock-in strategy
EDB Postgres ® AI Accelerates New Era of Sovereign Data and AI for Enterprises, Industries, and Nations17.6.2025 14:00:00 EEST | Press release
EnterpriseDB (EDB), the leading Postgres data and AI company, today announced new innovations to the EDB Postgres AI (EDB PG AI) platform designed to help enterprises deploy and scale AI securely and compliantly across their Postgres environments, whether in clouds or on-premises. The platform streamlines operations at scale, integrates easily with existing data ecosystems, and centralizes hybrid management and observability in a single AI-ready control plane for the emerging era of agentic AI. See the demonstrations and configure your sovereign AI and platform at www.enterprisedb.com. EDB PG AI is a unified platform with an easy-to-use interface for managing transactional, analytical, and AI workloads. As the industry’s first Postgres-based sovereign data and AI platform, it unifies relational and non-relational data in a single system, featuring automatic pipelines and built-in development tools that seamlessly automate and operationalize data for AI. “In this AI-first, sovereign-fir
G42 and Liquid AI Partner to Deliver Private, Local and Efficient AI Solutions to Enterprises at Scale17.6.2025 13:00:00 EEST | Press release
G42, the Abu Dhabi-based global technology group, and Liquid AI, a leading efficient foundation models company headquartered in Cambridge, Massachusetts, today announced that they have entered into a multifaceted commercial partnership to facilitate the creation, training and commercialization of generative AI solutions powered by Liquid Foundation Models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617744482/en/ The goal of the partnership is to jointly develop and deploy private generative AI solutions internationally, from the Middle East and North Africa to the Global South, and across many sectors, such as investment and banking, consumer electronics, telecommunications, biotech, and energy. G42 companies such as Core42 and Inception are involved in various aspects of the partnership, from AI infrastructure for AI development to co-designing multimodal foundation models and deployment. “This partnership reflects o
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)17.6.2025 11:28:00 EEST | Press release
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain. “We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to
Aqara Smart Lock U200 Lite Brings Smart Access Control to More European Households17.6.2025 10:00:00 EEST | Press release
Aqara, global leader and pioneer in IoT, unveils the new Smart Lock U200 Lite, offering effortless access control, enhanced security, and a modern keyless lifestyle to more European households, particularly those seeking budget-friendly solutions. Designed for DIY installation, the U200 Lite features a retrofit design compatible with most Euro mortise locks. It also supports Matter over Thread to ensure compatibility with a wide range of connected devices and seamless integration into users’ existing smart home setup. Built upon the Thread protocol, which is purposely developed for IoT devices, the Smart Lock U200 Lite is Matter-certified and integrates with major platforms – including Alexa, Apple Home, Google Home, Home Assistant, and SmartThings – without the need for a proprietary hub1. As an integral part of a connected home, the U200 Lite can be integrated with a variety of smart devices, from video doorbells, surveillance cameras to smart sensors, enabling users to create a cust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom